Degenerate minigene library analysis enables identification of altered branch point utilization by mutant splicing factor 3B1 (SF3B1)

被引:5
|
作者
Gupta, Abhishek K. [1 ]
Murthy, Tushar [2 ]
Paul, Kiran, V [1 ]
Ramirez, Oscar [1 ]
Fisher, Joseph B. [3 ]
Rao, Sridhar [3 ]
Rosenberg, Alexander B. [4 ]
Seelig, Georg [5 ]
Minella, Alex C. [3 ]
Pillai, Manoj M. [1 ]
机构
[1] Yale Canc Ctr, Sect Hematol, New Haven, CT 06520 USA
[2] Northwestern Univ, Driskill Grad Program, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Bloodctr Wisconsin, Blood Res Inst, Milwaukee, WI 53233 USA
[4] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA
[5] Univ Washington, Paul G Allen Sch Comp Sci & Engn, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
MUTATIONS; MYELODYSPLASIA; SELECTION;
D O I
10.1093/nar/gky1161
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer-associated mutations of the core splicing factor 3 B1 (SF3B1) result in selection of novel 3splice sites (3SS), but precise molecular mechanisms of oncogenesis remain unclear. SF3B1 stabilizes the interaction between U2 snRNP and branch point (BP) on the pre-mRNA. It has hence been speculated that a change in BP selection is the basis for novel 3SS selection. Direct quantitative determination of BP utilization is however technically challenging. To define BP utilization by SF3B1-mutant spliceosomes, we used an overexpression approach in human cells as well as a complementary strategy using isogenic murine embryonic stem cells with monoallelic K700E mutations constructed via CRISPR/Cas9-based genome editing and a dual vector homology-directed repair methodology. A synthetic minigene library with degenerate regions in 3 intronic regions (3.4 million individual minigenes) was used to compare BP usage of SF3B1(K700E) and SF3B1(WT). Using this model, we show that SF3B1(K700E) spliceosomes utilize non-canonical sequence variants (at position -1 relative to BP adenosine) more frequently than wild-type spliceosomes. These predictions were confirmed using minigene splicing assays. Our results suggest a model of BP utilization by mutant SF3B1 wherein it is able to utilize non-consensus alternative BP sequences by stabilizing weaker U2-BP interactions.
引用
收藏
页码:970 / 980
页数:11
相关论文
共 50 条
  • [21] Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes
    Volpe, Virginia O.
    Al Ali, Najla
    Chan, Onyee
    Padron, Eric
    Sallman, David A.
    Kuykendall, Andrew
    Sweet, Kendra
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (04) : 713 - 720
  • [22] Pan-cancer analysis identifies mutations in SUGP1 that recapitulate mutant SF3B1 splicing dysregulation
    Liu, Zhaoqi
    Zhang, Jian
    Sun, Yiwei
    Perea-Chamblee, Tomin E.
    Manley, James L.
    Rabadan, Raul
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (19) : 10305 - 10312
  • [23] SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
    Furney, Simon J.
    Pedersen, Malin
    Gentien, David
    Dumont, Amaury G.
    Rapinat, Audrey
    Desjardins, Laurence
    Turajlic, Samra
    Piperno-Neumann, Sophie
    de la Grange, Pierre
    Roman-Roman, Sergio
    Stern, Marc-Henri
    Marais, Richard
    CANCER DISCOVERY, 2013, 3 (10) : 1122 - 1129
  • [24] Mutant SF3B1 splices a more leukemogenic EVI1
    Obeng, Esther A.
    BLOOD, 2022, 140 (08) : 800 - 801
  • [25] SF3B1 Splicing Mutation in the Context of Therapy Related MDS
    Volpe, Virginia Olivia
    Al Ali, Najla
    Chan, Onyee
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    BLOOD, 2020, 136
  • [26] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    LABORATORY INVESTIGATION, 2014, 94 : 50A - 50A
  • [27] Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization
    Liu, Zhaoqi
    Yoshimi, Akihide
    Wang, Jiguang
    Cho, Hana
    Lee, Stanley Chun-Wei
    Ki, Michelle
    Bitner, Lillian
    Chu, Timothy
    Shah, Harshal
    Liu, Bo
    Mato, Anthony R.
    Ruvolo, Peter
    Fabbri, Giulia
    Pasqualucci, Laura
    Abdel-Wahab, Omar
    Rabadan, Raul
    CANCER DISCOVERY, 2020, 10 (06) : 806 - 821
  • [28] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    MODERN PATHOLOGY, 2014, 27 : 50A - 50A
  • [29] Role Of Sf3b1 On Hematopoiesis
    Matsunawa, Manabu
    Yamamoto, Ryo
    Sanada, Masashi
    Sato, Aiko
    Shiozawa, Yusuke
    Yoshida, Kenichi
    Nagata, Yasunobu
    Kon, Ayana
    Yoshizato, Tetsuichi
    Otsu, Makoto
    Isono, Kyoichi
    Koseki, Haruhiko
    Nakauchi, Hiromitsu
    Ogawa, Seishi
    BLOOD, 2013, 122 (21)
  • [30] Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization
    Yoshimi, Akihide
    Liu, Zhaoqi
    Wang Jiguang
    Cho, Hana
    Lee, Stanley C.
    Ki, Michelle
    Bitner, Lillian E.
    Chu, Timothy
    Mato, Anthony R.
    Ruvolo, Peter P.
    Fabbri, Giulia
    Pasqualucci, Laura
    Rabadan, Raul
    Abdel-Wahab, Omar I.
    BLOOD, 2018, 132